• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment - Product Image

Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment

  • Published: January 2013
  • Region: India
  • 94 Pages
  • GBI Research

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Biocon
  • Cipla Limited
  • Dr. Reddy’s Laboratories
  • GlaxoSmithKline
  • MORE

GBI Research's new report “Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment” provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market. Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years, the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 12% during the 2011–2015 period. Branded generics are expected to become more prevalent in India as many global players are planning to launch them after their patents expire.

The READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Indian Pharmaceutical Market Outlook – Introduction
3 Indian Pharmaceutical Market Outlook – Overview
3.1 Global Pharmaceutical Industry Landscape
3.2 Macro View of the Indian Pharmaceutical Sector
3.3 Demographic Analysis
3.3.1 Population Size, Growth, and Structure
3.3.2 Crude Death Rate
3.3.3 Infant Mortality Rate
3.3.4 Life Expectancy at Birth
3.4 Driver and Barriers
3.4.1 Drivers
3.4.2 Barriers
3.5 SWOT Analysis of Indian Pharmaceutical Industry
4 Indian Pharmaceutical Market Outlook – Industry Characteristics
4.1 Healthcare Policy
4.1.1 National Health Policy 2002
4.1.2 National Rural Health Mission
4.1.3 National Urban Health Mission
4.2 Intellectual Property Rights in India
4.2.1 Effect of Patent Laws on Pharmaceutical Production in India
4.2.2 Key Impact of the New Patent Laws on India
4.2.3 Patent Act 2005 – First Step towards Improving IP Protection
4.2.4 IPR Enforcement Rules 2007
4.2.5 Trademarks Bill 2007
4.2.6 Drugs and Cosmetics Act (Amendment) 2008
4.3 Drug Distribution Structure
4.4 National Pharmaceuticals Pricing Policy
4.4.1 Objectives of the Present Policy
4.4.2 Key Principles of National Pharmaceuticals Pricing Policy, 2011
4.4.3 Principles for Drug Price Control and Determination in National Pharmaceutical Pricing Policy 2011
4.4.4 Other Aspects of the Policy
4.4.5 Impact Analysis of the Policy
4.5 Goods and Services Tax
4.5.1 An Introduction to Goods and Services Tax
4.5.2 Dual Goods and Services Tax in India
4.5.3 Impact on the Pharmaceutical Industry
4.6 Direct Tax Code
4.6.1 Tax Structure
4.6.2 Incentives Available to the Pharmaceutical Sector
4.6.3 Road Ahead
4.7 Healthcare Spending in India
4.8 Insurance and Reimbursement
4.8.1 Private Health Insurance
4.8.2 Health Insurance Companies Landscape
5 Indian Pharmaceutical Market Outlook – Market Analysis
5.1 Market overview
5.1.1 Contract Research and Manufacturing Services
5.1.2 Biotech
5.1.3 Over-the-Counter Drugs
5.1.4 Prescription Drugs
5.1.5 Herbal Medicines
5.2 Market Segmentation
6 Indian Pharmaceutical Market Outlook – Market Analysis by Therapeutic Categories
6.1 Market Share of Leading Therapeutic Segment
6.2 Anti-Infectives
6.2.1 Market Size
6.2.2 Key Brands and Players
6.2.3 Recent Developments
6.2.4 Outlook
6.3 Cardiovascular System
6.3.1 Market Size
6.3.2 Recent Developments
6.3.3 Outlook
6.4 Gastrointestinal
6.4.1 Market Size
6.4.2 Recent Developments
6.4.3 Outlook
6.5 Diabetes
6.5.1 Market Size
6.5.2 Recent Developments
6.5.3 Outlook
6.6 Central Nervous System
6.6.1 Market Size
6.6.2 Recent Developments
6.6.3 Outlook
6.7 Respiratory
6.7.1 Market Size
6.7.2 Recent Developments
6.7.3 Outlook
6.8 Dermatology
6.8.1 Market Size
6.8.2 Recent Developments
6.8.3 Outlook
6.9 Oncology
6.9.1 Market Size
6.9.2 Recent Developments
6.9.3 Outlook
7 Indian Pharmaceutical Market Outlook – Key Trends
7.1 Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry
7.1.1 M&A Deals
7.1.2 Licensing Deals
7.1.3 Partnership Deals
7.2 Patent Litigations Favoring Generics
7.2.1 Indian Patent Office Revokes Patent for Pfizer's Cancer Drug Sutent (sunitinib)
7.2.2 Indian Appeals Body Dismisses Bayer's Plea for Stay on Natco's Generic Nexavar (sorafenib)
7.2.3 Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit
7.2.4 Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib)
7.3 Increasing Importance of Rural Marketing in India
7.3.1 Case Study - Novartis Arogya Parivar Case Study
7.4 Product Localization and India-Specific Pricing
7.4.1 Case Study - GlaxoSmithKline, Localized Business Model
7.5 Sales Strategies
7.5.1 Case Study - Mankind, Sales Excellence
7.6 Patented Products Introduced in Niche Segments
7.6.1 Case Study - Merck's Successful Strategy for Patented Products
7.7 Actions Taken by Indian Government against Counterfeit Drugs
8 Indian Pharmaceutical Market Outlook – Competitive Landscape
8.1 Key Foreign Companies
8.1.1 Sanofi
8.1.2 Roche
8.1.3 AstraZeneca
8.1.4 GlaxoSmithKline
8.1.5 Abbott Laboratories
8.2 Key Domestic Companies
8.2.1 Dr. Reddy's Laboratories
8.2.2 Lupin
8.2.3 Cipla Limited
8.2.4 Ranbaxy Laboratories Limited
8.2.5 Biocon
9 Indian Pharmaceutical Market Outlook – The Way Forward
9.1 Outlook for the Indian Pharmaceutical Industry
9.2 Risks
9.2.1 Currency Fluctuation and Financial Problems will make it Difficult to Sustain Growth
9.2.2 Regulatory Hurdles
9.2.3 Financial Disparity
9.2.4 Intellectual Property Concerns
9.3 Recommendations
9.3.1 Improved Links between Industry and Academia
9.3.2 Focus on R&D Initiatives and Skilled Manpower
9.3.3 Support for Clinical Trials Sector
9.3.4 Quality Drugs to be made Affordable and Accessible
9.4 Opportunities Ahead
9.5 Strategies for Future Success
9.5.1 Increasing Importance of Biosimilars
9.5.2 Rural Markets
10 Indian Pharmaceutical Market Outlook – Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables
Table 1: Pharmaceutical Market, India, Share of Pharmaceutical Products in Total Exports and Imports (%), 2012
Table 2: Pharmaceutical Market, India, Population by Age Group (%), 2001–2026
Table 3: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981–2009
Table 4: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980–1998
Table 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1999–2009
Table 6: Pharmaceutical Market, India, Ceiling Price Reduction and Impact, 2012
Table 7: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012
Table 8: Pharmaceutical Market, India, Indian Biosimilar Companies with Marketed Products in India, 2010
Table 9: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007–2011
Table 10: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007–2011
Table 11: Pharmaceutical Market, India, Anti-Infectives Market Revenue, ($bn), 2005–2010
Table 12: Pharmaceutical Market, India, Anti-Infectives, Major Companies and Brands, 2011
Table 13: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005–2010
Table 14: Pharmaceutical Market, India, Gastrointestinal Market Revenue, ($m), 2005–2010
Table 15: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005–2010
Table 16: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005–2010
Table 17: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005–2010
Table 18: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005–2010
Table 19: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005–2010
Table 20: Pharmaceutical Market, India, Dr. Reddy's Laboratories, Strategic Consolidations, 2011–2012
Table 21: Pharmaceutical Market, India, Lupin, Strategic Consolidations, 2011
Table 22: Pharmaceutical Market, India, Cipla, Strategic Consolidations, 2012
Table 23: Pharmaceutical Market, India, Ranbaxy, Strategic Consolidations, 2011–2012
Table 24: Pharmaceutical Market, India, Biocon, Strategic Consolidations, 2011–2012

1.2 List of Figures
Figure 1: Pharmaceutical Market, India, ANDA Filings by Indian Companies, 2012
Figure 2: Pharmaceutical Market, India, Growth in Pharmaceutical Products Trade, (%), 2006–2011
Figure 3: Pharmaceutical Market, India, Population by Age Group (%), 2001–2026
Figure 4: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981–2009
Figure 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980–2009
Figure 6: Pharmaceutical Market, India, Life Expectancy at Birth, 1901–2025
Figure 7: Pharmaceutical Market, India, Healthcare Indicators in BRIC Countries, 2012
Figure 8: Pharmaceutical Market, India, Drivers and Barriers, 2012
Figure 9: Pharmaceutical Market, India, Doctors and Nurses (per 10,000 population), 2010
Figure 10: Pharmaceutical Market, India, SWOT Analysis
Figure 11: Pharmaceutical Market, India, NRHM Progress, 2011
Figure 12: Pharmaceutical Market, India, Intellectual Property Rights Protection Framework, 2010
Figure 13: Pharmaceutical Market, India, Regulatory Landscape, Intellectual Property Rights Protection, 1963–2005
Figure 14: Pharmaceutical Market, India, Drug Distribution System, 2012
Figure 15: Pharmaceutical Market, India, Healthcare Expenditure, 2009
Figure 16: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012
Figure 17: Pharmaceutical Market, India, Health Insurance Companies Landscape, 2012
Figure 18: Pharmaceutical Market, India, Services Outsourced in Value Chain (%), 2011
Figure 19: Pharmaceutical Market, India, Biotechnology Market Revenue ($m), 2003–2011
Figure 20: Pharmaceutical Market, India, Biotechnology Market Segmentation (%), 2011
Figure 21: Pharmaceutical Market, India, Market by Sub-sector (%), 2011
Figure 22: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007–2011
Figure 23: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007–2011
Figure 24: Pharmaceutical Market, India, Market Share by Therapy Area, 2005 and 2010
Figure 25: Pharmaceutical Market, India, Anti-Infectives Market Revenue ($bn), 2005–2010
Figure 26: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005–2010
Figure 27: Pharmaceutical Market, India, Gastrointestinal Market Revenue ($m), 2005–2010
Figure 28: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005–2010
Figure 29: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005–2010
Figure 30: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005–2010
Figure 31: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005–2010
Figure 32: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005–2010
Figure 33: Pharmaceutical Market, India, Number of M&A Deals, 2007–2012
Figure 34: Pharmaceutical Market, India, M&A Deals, Deals by Value (%), 2007–2012
Figure 35: Pharmaceutical Market, India, Number of Licensing Deals, 2007–2012
Figure 36: Pharmaceutical Market, India, Licensing Deals, Deals by Value (%), 2007–2012
Figure 37: Pharmaceutical Market, India, Number of Partnership Deals, 2007–2012
Figure 38: Pharmaceutical Market, India, Partnership Deals, Deals by Value (%), 2007–2012
Figure 39: Pharmaceutical Market, India, Novartis Arogya Parivar Marketing Mix, 2012
Figure 40: Pharmaceutical Market, India, Novartis Arogya Parivar, Factsheet, 2012
Figure 41: Pharmaceutical Market, India, Mankind Sales Strategies, 2012

- Sanofi

- Roche

- AstraZeneca

- GlaxoSmithKline

- Abbott Laboratories

- Dr. Reddy’s Laboratories

- Lupin

- Cipla Limited

- Ranbaxy Laboratories Limited

- Biocon

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos